drugset
drugset / Trial / NCT06239155

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

NCT06239155 ↗

Phase 1/2 Active not recruiting 51 enrolled Ascentawits Pharmaceuticals, Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent

Timeline

Start
2019-09-03
Primary completion
2025-11-30
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject OBI-3424 Small molecule 1 mg/m2 Intravenous
Subject OBI-3424 Small molecule 2 mg/m2 Intravenous
Subject OBI-3424 Small molecule 4 mg/m2 Intravenous
Subject OBI-3424 Small molecule 6 mg/m2 Intravenous
Subject OBI-3424 Small molecule 10 mg/m2 Intravenous

Indications

hepatocellular carcinoma